CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that the Company will release its fourth quarter financial results on Thursday, February 14, 2008 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss its financial results, the progress of CUDC-101 and other drug candidates that Curis is developing under its Targeted Cancer Drug Development Platform, Curis’ Hedgehog-based product development programs under collaboration with Genentech and Wyeth, as well as additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
